CVKD
NASDAQ HealthcareCadrenal Therapeutics, Inc. - Common Stock
Biotechnology
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
�� 市场数据
| 价格 | $5.22 |
|---|---|
| 成交量 | 190,180 |
| 市值 | 13.09M |
| 贝塔系数 | 1.550 |
| RSI（14日） | 52.8 |
| 200日均线 | $9.95 |
| 50日均线 | $6.26 |
| 52周最高 | $17.50 |
| 52周最低 | $4.21 |
| Forward P/E | -1.34 |
| Price / Book | 4.46 |
🎯 投资策略评分
CVKD 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (98/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 🎈 Over-Hyped (13/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 CVKD in your text
粘贴任何文章、记录或帖子 — 工具将提取 CVKD 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.